BACKGROUND. Targeting CD30 with monoclonal antibodies in Hodgkin lymphoma (HL) and anaplastic large cell lymphoma (ALCL) has had profound clinical success. However, adverse events, mainly mediated by the toxin component of the conjugated antibodies, cause treatment discontinuation in many patients. Targeting CD30 with T cells expressing a CD30-specific chimeric antigen receptor (CAR) may reduce the side effects and augment antitumor activity.

中文翻译：

---

CD30特异性嵌合抗原受体重定向的淋巴细胞后的临床和免疫反应

背景。在霍奇金淋巴瘤（HL）和间变性大细胞淋巴瘤（ALCL）中用单克隆抗体靶向CD30已取得了巨大的临床成功。然而，主要由缀合抗体的毒素成分介导的不良事件导致许多患者中止治疗。用表达CD30特异性嵌合抗原受体（CAR）的T细胞靶向CD30可以减少副作用并增强抗肿瘤活性。